Gabapentin Capsule
Product Images NDC 76282-321

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 76282-321). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image100mg (Gabapentin Capsules 100mg)

This is a description of a medication called Gabapentin. It is available in capsule form containing 100mg of the active ingredient to treat specific conditions. The text includes details about the manufacturer and prescribing instructions for the medication.*

FDA Label Image

Gabapentin Capsules 300mg 1

Gabapentin Capsules USP is a prescription medication that is dispensed with an attached medication guide. Each capsule contains 300mg of gabapentin. The recommended dosage and usage information can be found in the package insert. The medication should be stored at 20° to 25°C (68° to 77°F) and it is manufactured by InvaGen Pharmaceuticals, Inc. for Exelan Pharmaceuticals, Inc.*

FDA Label Image

Gabapentin Capsules 300mg 2

This text describes a medication with the NDC code of 76282-627-90, which is a capsule containing 300 mg of Gabapentin. It indicates there is a package insert with full prescribing information, and the medication should be stored at controlled room temperature. The medication should be dispensed by a pharmacist with the attached medication guide. The medication is manufactured for the company EXELAN B Pamicetat, and is available by prescription only.*

FDA Label Image

Image400mg (Gabapentin Capsules 400mg)

FDA Label Image

Figure 1 (Gabapentin Capsules Fig01)

This is a table displaying the mean pain score for a 4-week dose titration period and a 4-week fixed dose period. The medications being compared are a placebo and Gabapentin, administered at a dosage of 3600mg/day. The numbers 1-8 represent the weeks of the study.*

FDA Label Image

Figure 2 (Gabapentin Capsules Fig02)

FDA Label Image

Figure 3 (Gabapentin Capsules Fig03)

This is a statistical figure representing the proportion of patients who responded to a certain treatment in two different studies related to PHN (Postherpetic Neuralgia). The data is displayed in a range from 0 to 100 in 10-point increments. The figure shows that in Study 1, 12% of patients had a reduction in pain score, while in Study 2, 32% had a reduction in pain score. The text also contains some monetary values, which may be relevant to the cost of treatment.*

FDA Label Image

Figure 4 (Gabapentin Capsules Fig04)

FDA Label Image

Formula (Gabapentin Capsules Formula)

This is a formula used to calculate creatinine clearance (CLCr) which is an important measure of kidney function. It takes into account the person's age and weight, as well as their serum creatinine level. Female patients need to multiply the result by 0.85.*

FDA Label Image

Structural Formula (Gabapentin Capsules Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.